三元基因(837344) - 2022 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2022 was CNY 170,998,937.09, a decrease of 15.18% compared to CNY 201,604,942.27 in the previous year[4] - The net profit attributable to shareholders was CNY 31,789,003.35, down 21.34% from CNY 40,414,576.19 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,561,129.55, a decrease of 6.85% compared to CNY 32,809,891.49 in the previous year[4] - Basic earnings per share were CNY 0.26, down 21.21% from CNY 0.33 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 930,362,961.14, an increase of 43.07% from CNY 650,273,778.58 at the beginning of the period[5] - Shareholders' equity attributable to the company was CNY 575,543,886.95, up 5.96% from CNY 543,170,952.35 at the beginning of the period[5] Impact of Pandemic - The decrease in revenue and net profit was primarily due to the impact of the pandemic, which led to a significant reduction in patient visits to hospitals[6] - The company expects sales to gradually improve following the relaxation of pandemic policies in December, although overall revenue for the year still declined compared to the previous year[8] Future Outlook and Notes - The growth in total assets was mainly driven by the advancement of the intelligent production base project for gene engineering drugs and R&D fundraising projects[8] - Investors are advised to note that the financial data for 2022 is preliminary and subject to audit, which may result in discrepancies[9]